Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Avere TherapeuticsPrivate | 1 asset: 1 Ph 2 | HS-20118Phase 2 · Psoriasis | 30 Oct 2026HS-20118 · Phase 1 |
 Avobis BioPrivate | 1 asset: 1 Ph 2 | AVB-114Phase 2 · Crohn's Disease | None on record |
 Axon NeurosciencePrivate | 1 asset: 1 Ph 2 | AADvac1Phase 2 · Alzheimer's DiseasePartial signal | None on record |
 Ayrmid Ltd.Private | 1 asset: 1 approved | Approved assets only | None on record |
 Beeline MedicinesPrivate | 1 asset: 1 Ph 2 | BMS-986322Phase 2 · PsoriasisPartial signal | None on record |
| 1 asset: 1 Ph 2 | BioTTT001Phase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2027BioTTT001 · Phase 1/2 | |
 Beijing Biostar Pharmaceuticals2563 · HKEX | 1 asset: 1 Ph 3 | UtidelonePhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Dec 2026Utidelone · Phase 2 |
Beijing Dongfang BiotechPrivate | 1 asset: 1 Ph 3 | exendin-4 Fc fusion (JY09)Phase 3 · Type 2 DiabetesWeak signal | None on record |
| 1 asset: 1 Ph 2 | GW117Phase 2 · Major Depressive DisorderPartial signal | None on record | |
 Beijing Inno MedicinePrivate | 1 asset: 1 Ph 2 | YN001Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | 31 Jul 2027YN001 · Phase 2 |
 Beijing Joekai BiotechnologyPrivate | 1 asset: 1 Ph 2 | 50561Phase 2 · Alzheimer's DiseasePartial signal | None on record |
| 1 asset: 1 Ph 1 | mulberry twig alkaloidsPhase 1 · ObesityWeak signal | None on record | |
 Benethera BiotechnologyPrivate | 1 asset: 1 Ph 1 | BDHK-2009Phase 1 · Ulcerative Colitis | None on record |
 BeyondBioPrivate | 1 asset: 1 Ph 2 | BEY2153Phase 2 · Alzheimer's DiseasePartial signal | Jul 2028BEY2153 · Phase 2 |
 BeyondSpring PharmaceuticalsBYSI · Nasdaq | 1 asset: 1 Ph 3 | PlinabulinPhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Jun 2029Plinabulin · Phase 3 |
 BioArctic ABPrivate | 1 asset: 1 Ph 2 | exidavnemabPhase 2 · Parkinson's DiseasePartial signal | None on record |
 BioCardiaBCDA · Nasdaq | 1 asset: 1 Ph 3 | CardiAMPPhase 3 · Heart FailurePartial signal | 1 Apr 2027CardiAMP · Phase na |
 BioCity BiopharmaceuticsPrivate | 1 asset: 1 Ph 3 | SC0062Phase 3 · Chronic Kidney Disease | 31 Dec 2026SC0062 · Phase 3 |
 BioEclipse TherapeuticsPrivate | 1 asset: 1 Ph 1 | CRX100Phase 1 · Non-Small Cell Lung Cancer | None on record |
 BioGenCellPrivate | 1 asset: 1 Ph 2 | BGC101Phase 1/2 · Atherosclerotic Cardiovascular Disease | None on record |
 BioInvent International ABBINV · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BI-1910Phase 1/2 · Non-Small Cell Lung Cancer | 14 Jul 2027BI-1910 · Phase 1/2 |
 BioLineRx Ltd.BLRX · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 BioLitePrivate | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 |
 BioTheryX, Inc.Private | 1 asset: 1 Ph 1 | BTX-9341Phase 1 · HR+/HER2- Metastatic Breast Cancer | 30 Sep 2027BTX-9341 · Phase 1 |
 BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq | 1 asset: 1 Ph 3 | BezisterimPhase 3 · Alzheimer's DiseasePartial signal | None on record |
 BiocodexPrivate | 1 asset: 1 approved | Approved assets only | Aug 2030Stiripentol · Phase 3 |
| 1 asset: 1 Ph 1 | Microlyvaq™Phase 1 · Non-Small Cell Lung Cancer | 2 Feb 2028Microlyvaq™ · Phase 1 | |
 Biomed IndustriesPrivate | 1 asset: 1 Ph 2 | NA-931Phase 2 · ObesityPartial signal | 15 Aug 2027NA-931 · Phase 2 |
 Bionyra PharmaPrivate | 1 asset: 1 Ph 1 | TL-003Phase 1 · Ulcerative Colitis | Apr 2027TL-003 · Phase 1 |
BiopeuticsPrivate | 1 asset: 1 Ph 3 | alprostadilPhase 3 · Heart FailurePartial signal | Nov 2029alprostadil · Phase 3 |
 BiosionPrivate | 1 asset: 1 Ph 2 | BSI-045BPhase 2 · Atopic DermatitisWeak signal | None on record |
 Biossil Inc.Private | 1 asset: 1 Ph 3 | SenicapocPhase 3 · Sickle Cell Disease | Jan 2029Senicapoc · Phase 2 |
 Biotroy TherapeuticsPrivate | 1 asset: 1 Ph 2 | BT02Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027BT02 · Phase 1 |
| 1 asset: 1 Ph 2 | BDTX-1535Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2028BDTX-1535 · Phase 2 | |
 BlueRock TherapeuticsPrivate | 1 asset: 1 Ph 3 | Bemdaneprocel (MSK-DA01)Phase 3 · Parkinson's DiseaseWeak signal | Mar 2027Bemdaneprocel (MSK-DA01) · Phase 3 |
 Bluefin BiomedicinePrivate | 1 asset: 1 Ph 3 | BFB759Phase 2/3 · Atopic Dermatitis | 28 Feb 2027BFB759 · Phase 2 |
 Blueprint MedicinesPrivate | 1 asset: 1 Ph 2 | BLU-924Phase 1/2 · Non-Small Cell Lung Cancer | Sep 2029BLU-924 · Phase 1/2 |
 BnH Research (Korea)Private | 1 asset: 1 Ph 1 | BnH-015BPhase 1 · Alzheimer's Disease | None on record |
 Boryung Pharmaceutical003850 · KOSPI | 1 asset: 1 Ph 3 | BR1017Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 BrexogenPrivate | 1 asset: 1 Ph 1 | BxC-I17ePhase 1 · Atopic Dermatitis | None on record |
 Bright Minds Biosciences Inc.DRUG · Nasdaq | 1 asset: 1 Ph 2 | BMB-101Phase 2 · Epilepsy | Nov 2026BMB-101 · Phase 2 |
 BrightPath Biotherapeutics Co., Ltd.4594 · TSE | 1 asset: 1 Ph 1 | BP2202Phase 1 · Multiple Myeloma | 31 Dec 2027BP2202 · Phase 1 |
 Byondis B.V.Private | 1 asset: 1 Ph 1 | BYON4413Phase 1 · Acute Myeloid Leukemia | None on record |
 C4 Therapeutics, Inc.CCCC · Nasdaq | 1 asset: 1 Ph 2 | CemsidomidePhase 2 · Multiple Myeloma | Dec 2028Cemsidomide · Phase 1 |
 CERo Therapeutics Holdings, Inc.CERO · OTC | 1 asset: 1 Ph 1 | CER-1236Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026CER-1236 · Phase 1 |
 CJ Bioscience, Inc.311690 · KOSDAQ | 1 asset: 1 Ph 2 | CJRB-101Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 CKD Bio CorporationPrivate | 1 asset: 1 other | L. lactis CKDB001Alzheimer's Disease | 31 May 2027L. lactis CKDB001 · Phase na |
 COMPASS PathwaysCMPS · Nasdaq | 1 asset: 1 Ph 3 | Psilocybin (COMP360)Phase 3 · Major Depressive DisorderReliable signal | Nov 2028Psilocybin (COMP360) · Phase 2/3 |
 CSPC Ouyi Pharmaceutical Co.Private | 1 asset: 1 Ph 3 | SYHX1901Phase 3 · PsoriasisPartial signal | 28 Apr 2027SYHX1901 · Phase 3 |
 CStone Pharmaceuticals2616 · HKEX | 1 asset: 1 Ph 3 | CS1001 Monoclonal AntibodyPhase 3 · Non-Small Cell Lung CancerReliable signal | None on record |
 Cajal TherapeuticsPrivate | 1 asset: 1 Ph 1 | CTX001 (Cajal)Phase 1 · Chronic Kidney Disease | None on record |
 Calico Life Sciences LLCPrivate | 1 asset: 1 Ph 1 | ABBV-CLS-484Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Candel Therapeutics, Inc.CADL · Nasdaq | 1 asset: 1 Ph 3 | Aglatimagene BesadenovecPhase 3 · Non-Small Cell Lung Cancer | Feb 2027Aglatimagene Besadenovec · Phase 2 |
 Cantargia ABCANTA · Nasdaq Stockholm | 1 asset: 1 Ph 2 | CAN04Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Capricor TherapeuticsCAPR · Nasdaq | 1 asset: 1 Ph 3 | deramiocelPhase 3 · Duchenne Muscular Dystrophy | None on record |
| 1 asset: 1 other | CAP-003Parkinson's Disease | None on record | |
Cara TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | 15 Aug 2029Difelikefalin · Phase 2 |
 Cardior Pharmaceuticals GmbHPrivate | 1 asset: 1 Ph 2 | CDR132LPhase 2 · Heart FailurePartial signal | 31 Dec 2026CDR132L · Phase 1 |
 Cardurion PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | TovinontrinePhase 2 · Heart FailurePartial signal | None on record |
 Carrick Therapeutics LimitedPrivate | 1 asset: 1 Ph 2 | SamuraciclibPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | None on record |
 Cartesian Therapeutics, Inc.RNAC · Nasdaq | 1 asset: 1 Ph 3 | Descartes-08Phase 3 · Myasthenia Gravis | 1 Dec 2026Descartes-08 · Phase 2 |
 CatalYm GmbHPrivate | 1 asset: 1 Ph 3 | VisugromabPhase 2/3 · Non-Small Cell Lung Cancer | 30 Apr 2028Visugromab · Phase 1/2 |
| 1 asset: 1 approved | Approved assets only | 6 Apr 2027Perampanel · Phase 2 | |
 Celavie Biosciences, LLCPrivate | 1 asset: 1 Ph 1 | OK99Phase 1 · Parkinson's DiseaseWeak signal | None on record |
 Celcuity Inc.CELC · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Gedatolisib · Phase 1/2 |
 CellCentric Ltd.Private | 1 asset: 1 Ph 3 | CCS1477Phase 3 · Multiple Myeloma | 31 Mar 2027CCS1477 · Phase 1/2 |
 Cellectar Biosciences, Inc.CLRB · Nasdaq | 1 asset: 1 Ph 3 | Iopofosine I-131Phase 3 · Waldenstrom's MacroglobulinemiaWeak signal | 30 Jun 2027Iopofosine I-131 · Phase 1 |
 Celularity Inc.CELU · Nasdaq | 1 asset: 1 Ph 2 | CYNK-001Phase 1/2 · Acute Myeloid Leukemia | None on record |
 Celyad Oncology SAPrivate | 1 asset: 1 Ph 1 | CYAD-211Phase 1 · Multiple Myeloma | None on record |
 Cenna BiosciencesPrivate | 1 asset: 1 Ph 1 | 8M2DPhase 1 · Alzheimer's Disease | Sep 20278M2D · Phase 1 |
| 1 asset: 1 Ph 3 | TricaprilinPhase 3 · Alzheimer's DiseasePartial signal | Jun 2029Tricaprilin · Phase 3 | |
 CerevancePrivate | 1 asset: 1 Ph 3 | Solengepras (CVN424)Phase 3 · Parkinson's DiseasePartial signal | None on record |
 CervoMed Inc.CRVO · Nasdaq | 1 asset: 1 Ph 2 | neflamapimodPhase 2 · Dementia with Lewy Bodies | None on record |
| 1 asset: 1 Ph 3 | Recombinant human growth hormonePhase 3 · Chronic Kidney DiseasePartial signal | None on record | |
| 1 asset: 1 Ph 3 | DA-302168SPhase 3 · ObesityPartial signal | 9 Jul 2027DA-302168S · Phase 3 | |
| 1 asset: 1 Ph 2 | ZhibitaiPhase 2 · Atherosclerotic Cardiovascular Disease | None on record | |
| 1 asset: 1 Ph 3 | YogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record | |
 China Resources Sanjiu Medical & Pharmaceutical000999 · SZSE | 1 asset: 1 Ph 3 | Shenfu injectionPhase 2/3 · Heart Failure | None on record |
 Chordia Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | CTX-712Phase 1/2 · Acute Myeloid Leukemia | Jun 2028CTX-712 · Phase 1/2 |
 Cirius TherapeuticsPrivate | 1 asset: 1 Ph 3 | MSDC-0602KPhase 3 · Type 2 DiabetesPartial signal | None on record |
 Clasp Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CLSP-5282Phase 1 · Non-Small Cell Lung Cancer | May 2029CLSP-5282 · Phase 1 |
 Clene NanomedicineCLNN · Nasdaq | 1 asset: 1 Ph 3 | CNM-Au8Phase 2/3 · Amyotrophic Lateral SclerosisPartial signal | None on record |
 Clexio BiosciencesPrivate | 1 asset: 1 Ph 2 | CLE-100Phase 2 · Major Depressive DisorderPartial signal | None on record |
 Climb Bio, Inc.CLYM · Nasdaq | 1 asset: 1 Ph 2 | budoprutugPhase 1/2 · Systemic Lupus Erythematosus | Apr 2027budoprutug · Phase 1 |
 CoRegen, Inc.Private | 1 asset: 1 Ph 2 | CRG-150Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | Jun 2029CRG-150 · Phase 1/2 |
 Cognition TherapeuticsCGTX · Nasdaq | 1 asset: 1 Ph 2 | ZervimesinePhase 2 · Alzheimer's DiseasePartial signal | 31 May 2027Zervimesine · Phase 2 |
 Coherus BioSciences, Inc.CHRS · Nasdaq | 1 asset: 1 approved | Approved assets only | 15 Dec 2026Toripalimab · Phase 1 |
 ConSynance TherapeuticsPrivate | 1 asset: 1 Ph 2 | CSTI-500Phase 2 · Obesity | Jun 2027CSTI-500 · Phase 2 |
 Concerto BiosciencesPrivate | 1 asset: 1 Ph 1 | ENS-002Phase 1 · Atopic DermatitisWeak signal | None on record |
 ConjuChemPrivate | 1 asset: 1 Ph 3 | CJC-1134-PCPhase 3 · Type 2 DiabetesPartial signal | None on record |
| 1 asset: 1 Ph 3 | CPO301Phase 3 · Non-Small Cell Lung Cancer | May 2027CPO301 · Phase 1 | |
 Connect BiopharmaCNTB · Nasdaq | 1 asset: 1 Ph 3 | RademikibartPhase 3 · Atopic DermatitisPartial signal | None on record |
 Consun Pharmaceutical Group1681 · HKEX | 1 asset: 1 Ph 1 | SK-08Phase 1 · Chronic Kidney Disease | None on record |
 CorMedixCRMD · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Taurolidine/heparin · Phase 3 |
 CorrectSequence TherapeuticsPrivate | 1 asset: 1 Ph 1 | CS-121Phase 1 · Atherosclerotic Cardiovascular Disease | Dec 2026CS-121 · Phase 1 |
| 1 asset: 1 Ph 1 | KRAS-specific Autologous TCR-T cellPhase 1 · Non-Small Cell Lung Cancer | 30 Nov 2028KRAS-specific Autologous TCR-T cell · Phase 1 | |
 Corsera HealthPrivate | 1 asset: 1 Ph 1 | COR-1004Phase 1 · Atherosclerotic Cardiovascular Disease | None on record |
 Corteria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | Corteria COR-1167Phase 2 · Heart Failure | None on record |
 Corxel PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | CX11Phase 3 · ObesityReliable signal | Mar 2027CX11 · Phase 1 |
 Cosette PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).